INTENSITY THERAPEUTICS, INC. Income Tax Expense
INTENSITY THERAPEUTICS, INC. (INTS) reported Income Tax Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-03-27
- INTENSITY THERAPEUTICS, INC. income tax expense (benefit) for fiscal 2025 was $0.00.
- INTENSITY THERAPEUTICS, INC. income tax expense (benefit) for fiscal 2024 was $0.00.
- INTENSITY THERAPEUTICS, INC. income tax expense (benefit) for fiscal 2023 was $0.00.
- INTENSITY THERAPEUTICS, INC. income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-27 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-27 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-13 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |